CoChat
Sign Up
Cited by 672

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model

Harrison, Ian F, Ismail, Ozama, Machhada, Asif, Colgan, Niall, Ohene, Yolanda, Nahavandi, Payam, Ahmed, Zeshan, Fisher, Alice, Meftah, Soraya, Murray, Tracey K, Ottersen, Ole P, Nagelhus, Erlend A, O’Neill, Michael J, Wells, Jack A, Lythgoe, Mark F·2020·Brain
DOI 10.1093/brain/awaa179PMC PMC7447521
Open this paper in CoChat — free account

Abstract

The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awaa179

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Heterogeneous deposition of tau in the cortex of rTg4510 mice. (A) NeuN and (B) CaMK2a expression in the mouse brain appear homogenous throughout rostral to caudal aspects of the cortex. During early deposition of tau in the rTg4510 mouse brain, however, pTau (PG-5) staining appears greater in the rostral compared to the caudal cortex, at (C) 3.2 months and (D) 3.7 months, subsiding by (E) 4.6 months of age. Subiculum of the hippocampus indicated with arrows on PG-5 staining images. Scale bar = 500 µm. (F) Quantification of the ratio of PG-5 immunoreactivity in the rostral and caudal cortex, and the somatomotor and visual cortex, reveal this pattern of elevated rostral compared to caudal tau deposition in the rTg4510 cortex during the early stages of deposition. n = 5–7 per group.
Figure 1 Heterogeneous deposition of tau in the cortex of rTg4510 mice. (A) NeuN and (B) CaMK2a expression in the mouse brain appear homogenous throughout rostral to caudal aspects of the cortex. During early deposition of tau in the rTg4510 mouse brain, however, pTau (PG-5) staining appears greater in the rostral compared to the caudal cortex, at (C) 3.2 months and (D) 3.7 months, subsiding by (E) 4.6 months of age. Subiculum of the hippocampus indicated with arrows on PG-5 staining images. Scale bar = 500 µm. (F) Quantification of the ratio of PG-5 immunoreactivity in the rostral and caudal cortex, and the somatomotor and visual cortex, reveal this pattern of elevated rostral compared to caudal tau deposition in the rTg4510 cortex during the early stages of deposition. n = 5–7 per group.CC BY · PubMed Central
Figure 2 Glymphatic inflow and clearance of tau from the mouse brain cortex. (A) MRI T1 signal intensity versus time data acquired from grey matter regions of the mouse brain showing differences in rates and intensities of glymphatic inflow of Gd-DTPA in anatomically discreet regions over time. (B) IntensityMax values (best-fit of maximal intensity achieved in region from sigmoidal fitting of data) in each of the brain regions in which raw data and sigmoidal curves are displayed in A. (C) MRI Gd-DTPA penetration efficiency (best-fit IntensityMax divided by Time50 values) in the rostral and caudal cortex, demonstrating the heterogeneity of the extent of glymphatic inflow into these two regions of the mouse cortex. (D) Schematic illustrating brain homogenate injection experiments in which tau containing brain homogenate was injected into either the rostral or caudal cortex, and CSF collected from the cisterna magna 60 min later. (E) Tau concentration of CSF samples collected in experiments shown schematically in D, demonstrating greater clearance of tau from the caudal compared to rostral aspect of the mouse cortex. Mean ± SEM of data and fitted curves shown in A, raw data and mean ± SEM between animals shown in E, and best-fit value and associated 95% CI of sigmoidal fitting of data shown in B and C. n = 5–8 per group. Statistical significance denoted by asterisks: ***P < 0.001, ****P < 0.0001.
Figure 2 Glymphatic inflow and clearance of tau from the mouse brain cortex. (A) MRI T1 signal intensity versus time data acquired from grey matter regions of the mouse brain showing differences in rates and intensities of glymphatic inflow of Gd-DTPA in anatomically discreet regions over time. (B) IntensityMax values (best-fit of maximal intensity achieved in region from sigmoidal fitting of data) in each of the brain regions in which raw data and sigmoidal curves are displayed in A. (C) MRI Gd-DTPA penetration efficiency (best-fit IntensityMax divided by Time50 values) in the rostral and caudal cortex, demonstrating the heterogeneity of the extent of glymphatic inflow into these two regions of the mouse cortex. (D) Schematic illustrating brain homogenate injection experiments in which tau containing brain homogenate was injected into either the rostral or caudal cortex, and CSF collected from the cisterna magna 60 min later. (E) Tau concentration of CSF samples collected in experiments shown schematically in D, demonstrating greater clearance of tau from the caudal compared to rostral aspect of the mouse cortex. Mean ± SEM of data and fitted curves shown in A, raw data and mean ± SEM between animals shown in E, and best-fit value and associated 95% CI of sigmoidal fitting of data shown in B and C. n = 5–8 per group. Statistical significance denoted by asterisks: ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 3 Altered CSF-ISF exchange in rTg4510 mice. (A) Representative pseudocolour scaled sagittal (∼0.5 mm lateral of bregma) images of a (A) wild-type and (B) rTg4510 mouse brain after cisterna magna infusion of Gd-DTPA, showing infiltration of contrast agent into the brain parenchyma. Scale bars = 1 mm. (C) MRI T1 signal intensity versus time data acquired from areas affected by tau pathology in the rTg4510 mouse model: the (Ci) caudal cortex, (Cii) rostral cortex and the (Ciii) hippocampus; and the (Civ) cerebellum, which is void of tau pathology in the mouse. Mean ± SEM of data and fitted curves shown. Extracted parameter of fitting displayed in Table 1. n = 5 per group. Statistical significance denoted by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 3 Altered CSF-ISF exchange in rTg4510 mice. (A) Representative pseudocolour scaled sagittal (∼0.5 mm lateral of bregma) images of a (A) wild-type and (B) rTg4510 mouse brain after cisterna magna infusion of Gd-DTPA, showing infiltration of contrast agent into the brain parenchyma. Scale bars = 1 mm. (C) MRI T1 signal intensity versus time data acquired from areas affected by tau pathology in the rTg4510 mouse model: the (Ci) caudal cortex, (Cii) rostral cortex and the (Ciii) hippocampus; and the (Civ) cerebellum, which is void of tau pathology in the mouse. Mean ± SEM of data and fitted curves shown. Extracted parameter of fitting displayed in Table 1. n = 5 per group. Statistical significance denoted by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Figure 4 Reduced glymphatic inflow and clearance of Tau in rTg4510 mice. (A) Schematic illustrating infusion of Gd-DTPA into the cisterna magna of the mouse for quantification of glymphatic inflow in the brain. (B) Representative pseudocolour scaled coronal (∼−2 mm from bregma) images of the (left) wild-type and (right) rTg4510 mouse brain, highlighting the difference in extent of contrast agent infiltration into the caudal cortex [designated by white arrows (wild-type) and arrowheards (rTg4510)] over time. This difference is further exemplified through the calculated Gd-DTPA penetration efficiency data shown in C. (D) Schematic illustrating brain homogenate injection experiments in which tau-containing brain homogenate was injected into either the rostral or caudal cortex of wild-type and rTg4510 mice, and CSF extracted from the cisterna magna 60 min later. (E) Tau concentration of CSF samples extracted from experiments shown schematically in D demonstrating reduced clearance from the caudal cortex of rTg4510 mice compared to wild-type animals. Raw data and mean ± SEM between animals shown in E, and best-fit value and associated 95% CI of sigmoidal fitting of data shown in C. n = 5–8 per group. Statistical significance denoted by asterisks: **P < 0.01, ****P < 0.0001.
Figure 4 Reduced glymphatic inflow and clearance of Tau in rTg4510 mice. (A) Schematic illustrating infusion of Gd-DTPA into the cisterna magna of the mouse for quantification of glymphatic inflow in the brain. (B) Representative pseudocolour scaled coronal (∼−2 mm from bregma) images of the (left) wild-type and (right) rTg4510 mouse brain, highlighting the difference in extent of contrast agent infiltration into the caudal cortex [designated by white arrows (wild-type) and arrowheards (rTg4510)] over time. This difference is further exemplified through the calculated Gd-DTPA penetration efficiency data shown in C. (D) Schematic illustrating brain homogenate injection experiments in which tau-containing brain homogenate was injected into either the rostral or caudal cortex of wild-type and rTg4510 mice, and CSF extracted from the cisterna magna 60 min later. (E) Tau concentration of CSF samples extracted from experiments shown schematically in D demonstrating reduced clearance from the caudal cortex of rTg4510 mice compared to wild-type animals. Raw data and mean ± SEM between animals shown in E, and best-fit value and associated 95% CI of sigmoidal fitting of data shown in C. n = 5–8 per group. Statistical significance denoted by asterisks: **P < 0.01, ****P < 0.0001.CC BY · PubMed Central
Figure 5 AQP4 expression and polarization in rTg4510 mice. Quantification of (A) mRNA and (B) protein expression of AQP4 in the rostral and caudal cortex of wild-type and rTg4510 mice, demonstrating upregulation in rTg4510 mice compared to wild-type controls. (C) Representative example images of brain tissue from wild-type and rTg4510 mice immunohistochemically stained for AQP4. Arrows indicate examples of immunopositive blood vessels in each image, which are shown at greater magnification in insets. (D) Representative immunofluorescence images of blood vessels in the caudal cortex of (Di) wild-type, and (Dii) rTg4510 mice stained for AQP4 and CD31, illustrating placement of 4-µm axis perpendicular to blood vessels for quantification of expression across vessel cross-sections, illustrating reduced AQP4 expression surrounding blood vessels in the caudal cortex of rTg4510 mice (E). (F) Quantification of AQP4 polarization similarly demonstrated reduced polarization to blood vessels in the caudal cortex of rTg4510 mice. This is further exemplified in caudal cortex sections stained for AQP4 and GFAP, demonstrating reduced endfoot AQP4 vessel coverage in the rTg4510 caudal cortex compared to wild-type (G). n = 5–9 per group. Statistical significance denoted by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 5 AQP4 expression and polarization in rTg4510 mice. Quantification of (A) mRNA and (B) protein expression of AQP4 in the rostral and caudal cortex of wild-type and rTg4510 mice, demonstrating upregulation in rTg4510 mice compared to wild-type controls. (C) Representative example images of brain tissue from wild-type and rTg4510 mice immunohistochemically stained for AQP4. Arrows indicate examples of immunopositive blood vessels in each image, which are shown at greater magnification in insets. (D) Representative immunofluorescence images of blood vessels in the caudal cortex of (Di) wild-type, and (Dii) rTg4510 mice stained for AQP4 and CD31, illustrating placement of 4-µm axis perpendicular to blood vessels for quantification of expression across vessel cross-sections, illustrating reduced AQP4 expression surrounding blood vessels in the caudal cortex of rTg4510 mice (E). (F) Quantification of AQP4 polarization similarly demonstrated reduced polarization to blood vessels in the caudal cortex of rTg4510 mice. This is further exemplified in caudal cortex sections stained for AQP4 and GFAP, demonstrating reduced endfoot AQP4 vessel coverage in the rTg4510 caudal cortex compared to wild-type (G). n = 5–9 per group. Statistical significance denoted by asterisks: *P < 0.05, **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Figure 6 Effect of pharmacological inhibition of AQP4 on CSF-ISF exchange and clearance of tau. (A) Timeline and (B) schematic illustrating experiments used to determine the effects of pharmacological inhibition of AQP4 on glymphatic inflow in the mouse brain. (C) MRI T1 signal intensity versus time data acquired from the (Ci) cortex, (Cii) striatum, (Ciii) hippocampus during these experiments, demonstrating significant inhibition of glymphatic inflow. (D) Timeline and (E) schematic illustrating experiments used to determine the effects of pharmacological inhibition of AQP4 on clearance of tau from the mouse brain. (F) Total tau and (G) pTau (pS199) concentration of CSF samples extracted from experiments shown schematically in D and E demonstrating reduced clearance of tau from the TGN-020 treated animal brain. Experiments repeated in a cohort of Aqp4−/− animals after TGN-020 or vehicle treatment, and CSF extracted 30 min post-injection for quantification of tau in CSF extracts. (H) CSF tau concentrations demonstrate the specific nature of TGN-020 towards AQP4, given the lack of an effect observed of TGN-020 in Aqp4−/− animals. Mean ± SEM of data and fitted curves shown in C, raw data and mean ± SEM between animals shown in F, G and H. n = 4–7 per group. Statistical significance denoted by asterisks: **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 6 Effect of pharmacological inhibition of AQP4 on CSF-ISF exchange and clearance of tau. (A) Timeline and (B) schematic illustrating experiments used to determine the effects of pharmacological inhibition of AQP4 on glymphatic inflow in the mouse brain. (C) MRI T1 signal intensity versus time data acquired from the (Ci) cortex, (Cii) striatum, (Ciii) hippocampus during these experiments, demonstrating significant inhibition of glymphatic inflow. (D) Timeline and (E) schematic illustrating experiments used to determine the effects of pharmacological inhibition of AQP4 on clearance of tau from the mouse brain. (F) Total tau and (G) pTau (pS199) concentration of CSF samples extracted from experiments shown schematically in D and E demonstrating reduced clearance of tau from the TGN-020 treated animal brain. Experiments repeated in a cohort of Aqp4−/− animals after TGN-020 or vehicle treatment, and CSF extracted 30 min post-injection for quantification of tau in CSF extracts. (H) CSF tau concentrations demonstrate the specific nature of TGN-020 towards AQP4, given the lack of an effect observed of TGN-020 in Aqp4−/− animals. Mean ± SEM of data and fitted curves shown in C, raw data and mean ± SEM between animals shown in F, G and H. n = 4–7 per group. Statistical significance denoted by asterisks: **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 41

  1. Achariyar, 2016, Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation, Mol Neurodegener, 11, 74, 10.1186/s13024-016-0138-8 · DOI
  2. Ahmed, 2014, A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity, Acta Neuropathol, 127, 667, 10.1007/s00401-014-1254-6 · DOI
  3. Amiry-Moghaddam, 2004, Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport, Neuroscience, 129, 997, 10.1016/j.neuroscience.2004.08.049 · DOI
  4. Amiry-Moghaddam, 2003, An α-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain, Proc Natl Acad Sci USA, 100, 2106, 10.1073/pnas.0437946100 · DOI · Paper page
  5. Bedussi, 2016, Paravascular channels, cisterns, and the subarachnoid space in the rat brain: a single compartment with preferential pathways, J Cereb Blood Flow Metab, 37, 1374, 10.1177/0271678X16655550 · DOI
  6. Bloch, 2006, Accelerated progression of Kaolin-induced hydrocephalus in aquaporin-4-deficient mice, J Cereb Blood Flow Metab, 26, 1527, 10.1038/sj.jcbfm.9600306 · DOI
  7. Braak, 1995, Staging of Alzheimer’s disease-related neurofibrillary changes, Neurobiol Aging, 16, 271, 10.1016/0197-4580(95)00021-6 · DOI · Paper page
  8. Camassa, 2015, Mechanisms underlying AQP4 accumulation in astrocyte endfeet, Glia, 63, 2073, 10.1002/glia.22878 · DOI
  9. Chesser, 2013, Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease, Front Neurol, 4
  10. Gaberel, 2014, Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRI: a new target for fibrinolysis?, Stroke, 45, 3092, 10.1161/STROKEAHA.114.006617 · DOI
  11. Giannakopoulos, 2003, Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease, Neurology, 60, 1495, 10.1212/01.WNL.0000063311.58879.01 · DOI · Paper page
  12. Glabe, 2001, Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer’s disease, J Mol Neurosci, 17, 137, 10.1385/JMN:17:2:137 · DOI · Paper page
  13. Goedert, 2017, Propagation of tau aggregates and neurodegeneration, Annu Rev Neurosci, 40, 189, 10.1146/annurev-neuro-072116-031153 · DOI · Paper page
  14. Hadjihambi, 2019, Impaired brain glymphatic flow in experimental hepatic encephalopathy, J Hepatol, 70, 40, 10.1016/j.jhep.2018.08.021 · DOI
  15. Hawkes, 2014, Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy, Brain Pathol, 24, 396, 10.1111/bpa.12159 · DOI
  16. Holmes, 2016, Imaging the accumulation and suppression of tau pathology using multiparametric MRI, Neurobiol Aging, 39, 184, 10.1016/j.neurobiolaging.2015.12.001 · DOI · Paper page
  17. Holter, 2017, Interstitial solute transport in 3D reconstructed neuropil occurs by diffusion rather than bulk flow, Proc Natl Acad Sci USA, 114, 9894, 10.1073/pnas.1706942114 · DOI · Paper page
  18. Huber, 2009, Identification of aquaporin 4 inhibitors using in vitro and in silico methods, Bioorg Med Chem, 17, 411, 10.1016/j.bmc.2007.12.040 · DOI
  19. Igarashi, 2013, Inhibition of aquaporin-4 significantly increases regional cerebral blood flow, Neuroreport, 24, 324, 10.1097/WNR.0b013e32835fc827 · DOI
  20. Iliff, 2014, Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury, J Neurosci, 34, 16180, 10.1523/JNEUROSCI.3020-14.2014 · DOI · Paper page
  21. Lewis, 2016, Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies, Acta Neuropathol, 131, 27, 10.1007/s00401-015-1507-z · DOI
  22. Louveau, 2017, Understanding the functions and relationships of the glymphatic system and meningeal lymphatics, J Clin Invest, 127, 3210, 10.1172/JCI90603 · DOI · Paper page
  23. Lundgaard, 2016, Glymphatic clearance controls state-dependent changes in brain lactate concentration, J Cereb Blood Flow Metab, 37, 2112, 10.1177/0271678X16661202 · DOI
  24. Matarin, 2015, A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology, Cell Rep, 10, 633, 10.1016/j.celrep.2014.12.041 · DOI · Paper page
  25. Medina, 2014, The role of extracellular Tau in the spreading of neurofibrillary pathology, Front Cell Neurosci, 8, 113, 10.3389/fncel.2014.00113 · DOI · Paper page
  26. Mestre, 2018, Aquaporin-4-dependent glymphatic solute transport in the rodent brain, eLife, 7, e40070, 10.7554/eLife.40070 · DOI · Paper page
  27. Nedergaard, 2013, Garbage truck of the brain, Science, 340, 1529, 10.1126/science.1240514 · DOI · Paper page
  28. Peng, 2016, Suppression of glymphatic fluid transport in a mouse model of Alzheimer’s disease, Neurobiol Dis, 93, 215, 10.1016/j.nbd.2016.05.015 · DOI · Paper page
  29. Plog, 2015, Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system, J Neurosci, 35, 518, 10.1523/JNEUROSCI.3742-14.2015 · DOI · Paper page
  30. Ramsden, 2005, Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L), J Neurosci, 25, 10637, 10.1523/JNEUROSCI.3279-05.2005 · DOI · Paper page
  31. Smith, 2018, The “glymphatic” mechanism for solute clearance in Alzheimer’s disease: game changer or unproven speculation?, FASEB J, 32, 543, 10.1096/fj.201700999 · DOI
  32. Syková, 2005, Changes in extracellular space size and geometry in APP23 transgenic mice: A model of Alzheimer’s disease, Proc Natl Acad Sci USA, 102, 479, 10.1073/pnas.0408235102 · DOI · Paper page
  33. Tarasoff-Conway, 2015, Clearance systems in the brain-implications for Alzheimer disease, Nat Rev Neurol, 11, 457, 10.1038/nrneurol.2015.119 · DOI · Paper page
  34. Verkman, 2017, Aquaporin water channels and hydrocephalus, Pediatr Neurosurg, 52, 409, 10.1159/000452168 · DOI
  35. Weller, 2008, SYMPOSIUM: clearance of Aβ from the brain in Alzheimer’s Disease: perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease, Brain Pathol, 18, 253, 10.1111/j.1750-3639.2008.00133.x · DOI
  36. Wu, 2016, Neuronal activity enhances tau propagation and tau pathology in vivo, Nat Neurosci, 19, 1085, 10.1038/nn.4328 · DOI · Paper page
  37. Xiong, 2017, Precise cerebral vascular Atlas in stereotaxic coordinates of whole mouse brain, Front Neuroanat, 11, 128, 10.3389/fnana.2017.00128 · DOI
  38. Xu, 2015, Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits, Mol Neurodegener, 10, 58, 10.1186/s13024-015-0056-1 · DOI · Paper page
  39. Yang, 2011, Loss of astrocyte polarization in the Tg-ArcSwe mouse model of Alzheimer’s disease, J Alzheimers Dis, 27, 711, 10.3233/JAD-2011-110725 · DOI
  40. Zemlan, 2002, C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome, Brain Res, 947, 131, 10.1016/S0006-8993(02)02920-7 · DOI
  41. Zeppenfeld, 2016, Association of perivascular localization of aquaporin-4 with cognition and alzheimer disease in aging brains, JAMA Neurol, 74, 91, 10.1001/jamaneurol.2016.4370 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Harrison, I. F., Ismail, O., Machhada, A., Colgan, N., Ohene, Y., Nahavandi, P., Ahmed, Z., Fisher, A., Meftah, S., Murray, T. K., Ottersen, O. P., Nagelhus, E. A., O’Neill, M. J., Wells, J. A., & Lythgoe, M. F.
Affiliations
  • UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK
  • Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK
  • Office of the President, Karolinska Institutet, Stockholm, Sweden
  • Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
ORCID
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2020-07-23
Volume
143
Issue
8
Pages
2576-2593
ISSN
  • 0006-8950
  • 1460-2156
DOI
10.1093/brain/awaa179
PMC
PMC7447521
Cited by
672
References
19
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 1 d)
Funders
  • Eli Lilly and Company
  • Engineering and Physical Sciences Research Council
  • EPSRC (EP/N034864/1)
  • Alzheimer’s Research UK (ARUK-RF2019A-003)
  • Parkinson’s UK
  • Wellcome Trust
  • Royal Society Sir Henry Dale Fellowship (204624/Z/16/Z)
  • King’s College London
  • UCL Comprehensive Cancer Imaging Centre
  • Regenerative Medicine Platform Safety Hub (MR/K026739/1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review